- Stephen J. Annest
- William C. Brown, MD
- Raymond N. Blum, MD
- Jennifer Clark, MD
- Wendy Gill, MD
- David B. Hahn, MD
- Ioana Hinshaw, MD
- Ronald R. Hugate, MD
- Cynthia Kelly, MD
- Omar Mubarak, MD
- Lisa R. Nowak, MD
- David P. Schnur, MD
- Alan Y. Synn, MD
- Matthew Terra, MD
- Conrad J. Tirre, MD
- Ross M. Wilkins, MD, MS
- Julie D. Zimbelman, MD
| Jennifer Clark, MD |
|
CURRICULUM VITAE
Office: Rocky Mountain Pediatric Hematology/Oncology Place of Birth: Denver, Colorado Education 1987-1991 B.S. Colorado State University, Fort Collins, CO (magna cum laude, with Honors) 1992-1996 M.D. Johns Hopkins University School of Medicine, Baltimore, MD (Alpha Omega Alpha)
Postdoctoral Training 1996-1997 Intern in Harvard Combined Residency in Medicine and Pediatrics, Brigham and Women's Hospital, Boston Children's Hospital, and Massachusetts General Hospital, Boston, MA 1997-2000 Resident in Harvard Combined Residency in Medicine and Pediatrics, Brigham and Women's Hospital, Boston Children's Hospital, and Massachusetts General Hospital, Boston, MA 2000-2001 Clinical Fellow in Pediatric Hematology and Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, MA 2001-2003 Research Fellow in Pediatric Hematology and Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, MA 2002-2003 Chief Fellow for Pediatric Hematology and Oncology Fellowship at Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, MA
Licensure and Certification:
1998 Commonwealth of Massachusetts Medical
1998 United States Drug Enforcement Agency
1998 Commonwealth of Massachusetts Controlled
2000 Board certification in General Pediatrics from
2000 Board certification in Internal Medicine by the 2003 CITI certification in Responsible Research
2004 Board certification in Pediatric Hematology and
2007 State of Colorado Medical License Registration
2007 Recertification in General Pediatrics from the
Hospital or Affiliated Institution Appointments
2001-2007 Attending Physician in Pediatrics, Winchester
2003-2007 Attending Physician in Pediatric Hematology,
2003-2007 Attending Physician in Pediatric Hematology, Myelogenous Leukemia at Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, MA
2005-2007 Director of Outpatient Clinic for Pediatric
2007-present HCA/HealthONW, Presbyterian/St. Luke's Committee Assignments:
2002-2003 Clinical Restructuring Committee, Dana Farber 2003-2007 IRB Panel C, review of Serious Adverse Events, Violations, and Continuing Reviews, Dana Farber Cancer Institute, Boston, MA
Professional Societies: 2000-2006 Massachusetts Medical Society 2003-2007 Children's Oncology Group through Dana Farber Cancer Institute 2008-present Children's Oncology Group membershipthrough Rocky Mountain Hospital for Children at Presbyterian/St. Luke's Medical Center
Editorial Boards: 2002-present Journal of Pediatric Hematology/Oncology, adhoc reviewer 2003-present American Journal of Hematology, ad hoc reviewer
Awards and Honors:
1987-1991 Boettcher Scholarship recipient, Colorado
1988 Golden Key Honor Society, Colorado State
1989 Phi Sigma Iota (foreign language honor
1989 Phi Kappa Phi (academic honor society), 1990 Phi Beta Kappa, Colorado State University
1991 Graduated Magna Cum Laude and with Honors,
1996 Alpha Omega Alpha, Johns Hopkins University Part II: Research, Teaching, and Clinical Contributions
Narrative Report I currently practice Pediatric Hematology/Oncology in the Rocky Mountain Pediatric Hematology/Oncology practice located at Presbyterian/St. Luke's. I also work with the adult bone marrow transplantation program at Rocky Mountain Cancer Center.
Funding Information - Research Sept 2004 - Aug 2005 Mentored Patient-Oriented Research Career Development Award K23 CA109408 (PI), "Sensitivity of various FLT3 mutations to FLT3 inhibitors"
Report of Research Activities Laboratory:
K23-CA109408-01 Sensitivity of various FLT3 mutations to
DFCI 04-012 Murine Models of Hematopoietic
Clinical Trials: DFCI 04-172 AML 2002: A collaborative Trial for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia (St. Jude). Local PI. DFCI 03-040 Gemtuzumab Ozogamicin for patients withAML (COG). Local PI. DFCI 00-140 Arsenic Trioxide in Refractory Leukemia or Lymphoma (COG). Local PI. DFCI 00-137 Treatment of Downs Syndrome and AML, AMD,or TMD (COG). Local PI.
DFCI 04-166 Galactomannan Enzyme Linked Immunoassay as an early indicator of fungal disease. Collaborating investigator. DFCI 04-118 Caspofungin versus Amphotericin for Fever and Neutropenia. Collaborating investigator. DFCI 03-414 Caspofungin in Children with Fungal Infections. Collaborating investigator. DFCI 03-292 Phase I Decitabine for Relapsed/Refractory Leukemia. Collaborating investigator.
Report of Teaching 2002-2003 Chief fellow for Pediatric Hematology/Oncology fellowship. 2002-2007 First year fellow Oncology Course. Lecturer. 2003-2007 First year fellow Hematology Course. Lecturer. myelodysplastic syndrome and acute myeloid leukemia. 2002-2007 Second year fellow summer course. Lecturer. 2002-2007 Pediatric Oncology Conference. Lecturer. 2004-2006 Advisor one second year and one third year fellow. 2007 CPON conference lecture on Acute Myeloid Leukemia. 2007-present Teaching sessions for nursing staff, primary care residents, and practicing pediatricians on anemia, lymphadenopathy, neutropenia, oncologic emergencies, work-up of bleeding, and acute myeloid leukemia
Report of Clinical Activities 2003-2005 Attending Physician in outpatient Pediatric Hematology clinic at Boston Children's Hospital, seeing primary patients one afternoon per month. 2003-2007 Attending Physician in outpatient Pediatric Hematopoietic Stem Cell Transplantation clinic at the Jimmy Fund Clinic, Dana Farber Cancer Institute seeing primary patients, supervising fellows, NPs, PAs in the care of patients, and working up new referrals to the center. 2003-2007 Attending Physician in inpatient Pediatric Hematopoietic Stem Cell Transplantation supervising fellows, residents, NPs, and PAs for 8 weeks and 6 weekends per year 2003-2007 Disease Specific Attending for Pediatric Acute Myelogenous Leukemia inpatient at Boston Children's Hospital and outpatient at the Jimmy Fund Clinic at Dana-Farber Cancer Institute. Diagnosis of de novo and relapsed AML (including APML), enrollment of patients on clinical trials as appropriate, decisions regarding treatment plans for patients, supervising fellow and resident care of patients. 2005-2007 Director of Outpatient Clinic for Pediatric Hematopoietic Stem Cell Transplantation. 2007-present General Pediatric Hematology/Oncology at Rocky Mountain Pediatric Hematology/Oncology at Presbyterian/St. Luke's. 2007-present Collaboration with adult bone marrow transplantation program at Rocky Mountain Cancer Center.
Part III: BIBLIOGRAPHY
Original Articles 1. Stone RM, De Angelo J, Galinsky I, Estey E, Klimek V, Grandin W, Lebwohl D, Yap A, Cohen P, Fox E, Neuberg D, Clark J, Gilliland DG, Griffin JD. PKC412 FLT3 inhibitor therapy in AML: results of a phase II trial. Ann Hematol. 2004;83 Suppl 1:S89-90.
2. Geva A, Clark JJ, Zhang Y, Popowicz A, Manning JM, Neufeld EJ. Hemoglobin Jamaica plain--a sickling hemoglobin with reduced oxygen affinity. N Engl J Med. 2004 Oct 7;351(15):1532-8.
3. Clark JJ, Cools J, Curley DP, Yu JC, Lokker NA, Giese NA, Gilliland DG. Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood. 2004 Nov 1;104(9):2867-2872.
4. Levine, RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MW. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005 Nov 15;106(10):3377-9.
5. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr;7(4):387-97. 6. Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, Griffin JD, Gilliland DG. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood. 2005 Jul 15;106(2):721-4. 7. Cools J, Mentens N, Furet P, Fabbro D, Clark JJ, Griffin JD, Marynen P, Gilliland DG. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res. 2004 Sep 15;64(18):6385-9. 8. Stone RM, De Angelo J, Galinsky I, Estey E, Klimek V, Grandin W, Lebwohl D, Yap A, Cohen P, Fox E, Neuberg D, Clark J, Gilliland DG, Griffin JD. PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial. Ann Hematol. 2004;83 Suppl 1:S89-90. 9. Clark JCools J, Gilliland DG. EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head. PLoS Med. 2005 Mar;2(3):e75. 10. Cools J, Mentens N, Furet P, Fabbro D, Clark JJ, Griffin JD, Marynen P, Gilliland DG. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res. 2004 Sep 15;64(18):6385-9.
Reviews: 1. Kelly L, Clark J, Gilliland DG. Comprehensive genotypic analysis of leukemia: clinical and therapeutic implications. Current Opinion Oncology. 2002:14:10-18.
2. Clark JJ, Smith FO, Arceci RJ. Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies. Current Opinion Hematology. 2003;10(1):31-9 |
|
| Last Updated ( Monday, 13 April 2009 ) |
Dr. Jennifer Clark is a pediatric hematologist oncologist with the Rocky Mountain Pediatric Hematology Oncology Clinic. She attended medical school at the John Hopkins University School of Medicine, Baltimore MD and her pediatric residence in Harvard Combined Residency in Medicine and Pediatrics, Brigham and Women’s Hospital, Boston Children’s Hospital and Massachusetts General Hospital, Boston MA. In addition she completed her fellowship in hematology-oncology at Boston Children’s Hospital and Dana-Farber Cancer Institute in Boston MA.